NIK-333 (Peretinoin) Phase III Study Investigation of the Efficacy and Safety to Suppress Recurrence of Hepatitis C Virus (HCV)-Positive Hepatocellular Carcinoma (HCC), Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group Study

Trial Profile

NIK-333 (Peretinoin) Phase III Study Investigation of the Efficacy and Safety to Suppress Recurrence of Hepatitis C Virus (HCV)-Positive Hepatocellular Carcinoma (HCC), Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Peretinoin (Primary)
  • Indications Hepatitis C; Liver cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Kowa Pharmaceutical
  • Most Recent Events

    • 23 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 23 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top